Obermatt
See Similar Stocks →

Erasca

NSQ:ERAS · US29479A1088
BiotechnologySmall

360° View

no current rank
Price/Sales—
Price/Earnings95
Price/Book13
Dividend Yield—
Revenue Growth—
Profit Growth38
Capital Growth94
TSR 52w100
Leverage47
Liquidity21
Refinancing83
Combined—
Analyst Opinions11
Pro Holdings53
Opinion Changes50
Market Pulse21

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2018
Employees112
Websiteerasca.com
ISINUS29479A1088
Last UpdateApr 2, 2026
Index & Theme
GeneticsCentral Nervous SystemOncologyBiotechnologyEmergency MedicineHealth CareLife Science

Description

Erasca, Inc. is a clinical-stage precision oncology company. The company is singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s focused RAS/MAPK pathway pipeli…

Similar Stocks

The companies this stock is ranked against.

Compare Erasca with its peers
RAPT Therapeutics
NMQ:RAPT
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Monte Rosa Therapeutics
NSQ:GLUE
13
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Day One Biopharmaceuticals
NSQ:DAWN
39
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Palvella Therapeutics
NAQ:PVLA
100
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Immuneering
NMQ:IMRX
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Elicio Therapeutics
NAQ:ELTX
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →